Gilead enlists Cancer Genetics to perform leukemia trials

Gilead Sciences appointed Cancer Genetics to head up international clinical trials in an effort to diagnose patients with chronic lymphocytic leukemia. Using its SelectOne program, Cancer Genetics will use diagnostic assays and microarrays in a series of tests for cancer-specific biomarkers associated with leukemia. Chronic lymphocytic leukemia is the most common from of the disease in the western hemisphere and affects over 110,000 people in the U.S., according to Cancer Genetics. More